“Imagine if vaccines didn’t have to be formulated as liquids. Imagine if they were cheap, safe, fast and agile to transport with no cold chain necessary, and nothing holding them back. Imagine the suffering that could be prevented, the costs that could be avoided and the communities and societies that could be set free. That, ultimately, is what Ziccum technology can deliver.” – Göran Conradson, CEO, ZICCUM

Ziccum is developing new dry-powder versions of the world’s most effective vaccines from bulk containers to convenient forms for administrations. These new, gently air-dried powder vaccines can be transported easily and cost-effectively, with no costly cold storage or refrigeration required.

With the company's patented technology LaminarPace, dry formulations of products that are currently available in liquid, or freeze-dried form are developed. This allows Ziccum to open up new markets, create new patents and generate revenue from the sale of licenses to the new form of preparation.

Through its patented technology LaminarPace, Ziccum is the only company in the world to offer gentle drying of vaccines at room temperature. This opens up the opportunity to develop and patent new processes of vaccines and offer better stability, longer durability and simpler storage and transportation requirements. This gives a competitive advantage, cost savings and the opportunity to address more and bigger markets. New forms of preparation and the process of producing these can also be protected by new patents so that the competitive advantage lasts over time. LaminarPace has been validated through internal, published studies and external projects where Ziccum has carried out feasibility studies on behalf of the client.

The company intends to license out rights to its IP portfolio, but also look at the value creation chain as a whole and investigate different options and possibilities to move up and take a larger portion of the value created. Through International partnerships and larger contracts spanning over several stake holders within the industry.

Ziccum, located in Lund, was founded as a spinout from Inhalation Sciences, which was successfully listed on Spotlight in September 2017. Ziccum followed the same path and was listed on Spotlight in October 25th, 2018, and from December 1st, 2020 listed on Nasdaq First North Growth Market,

For additional information about Ziccum please visit the company website: http://www.ziccum.com


Director Business Development

“Set vaccines free”

Ziccums vision is to provide safe and effective vaccines in all environments and situations worldwide and to minimize expensive and impractical fridge and freezer transport and storage.

Do you have a desire to be a leading part of an innovative entrepreneur company working with products that both creates attention but also contribute to developing new dry-powder versions of the world’s most urgently needed vaccines? These new, gently air-dried formulations can be transported easily and cost-effectively, with no costly cold storage or refrigeration required. Ziccum has the technology to make a significant difference for large populations who need access to vaccines and drugs, and for large pharmaceutical companies that want to streamline the logistics of their products and thereby increase market potential.

With Ziccum’s unique and patented technology, LaminarPace® objective is to develop new formulations of vaccines. By developing dry formulations of products presently present only in liquid, or in freeze-dried form, Ziccum can open new markets and create new patents. Dry form is always sought in the development of new drugs. The benefits of dry form (tablets, powders, etc.) are many. It increases the stability of the product and thus its life span, it facilitates the entire transport chain from factory to patient, enabling the distribution of drugs to new locations where, for example, refrigerator and freezer storage is a major challenge. The company focus on a market (biologics) where the history, trends and needs clearly indicates the value of being able to produce products in dry form but where the technical solutions for doing this has been lacking.
Currently Ziccum is focusing on the next step – to adapt the technology for commercial production and present our offer to potential partners in the pharmaceutical industry.

The product – the patented technology LaminarPace
LaminarPace is a patented technology that gently dries chemicals, vaccines, biologics and drug substances at room temperature, keeping their active ingredient intact. The technology has successfully dried over 100 different types of biologics and chemicals, including viruses and antibodies. Current conventional drying technologies either freeze or bake substances. Operating at -80 °C or +80 °C means there is little chance of delicate, temperature-sensitive materials, like vaccines, remaining active after being dried. By micronizing substances at room temperature, LaminarPace produces robust, active dry powder versions of delicate biologics, peptides, proteins and antibodies. The current formulation for all vaccines requires 4-8oC temperature storage from plant to patient, making them costly and difficult to handle and transport.

The market for biological drugs is large and in strong growth. In 2017, biological drugs accounted for one third of total drug sales globally, equivalent to $ 208 billion. By 2024, this figure is estimated to have increased to $ 380 billion or 38% of global pharmaceutical sales. [EvaluatePharma® World Preview 2018, Outlook to 2024, 11th Edition - June 2018]. The market for vaccines is $ 45 billion and is expected to significantly grow with 7%/year and an additional strong growth with new vaccines for Covid-19. Today about 5 billion vaccine doses are manufactured every year and an additional 15-20 billion covid-19 doses are expected to be produced.

The position
CEO Göran Conradson: “In a larger context, this recruitment is a continuation to move our position from an entrepreneurial technology company to a process-oriented vaccine company, with an increased focus on Covid-19 manufacturers.”

We are looking for an energetic and driven Director of Business Development to expand current relationships as well as drive revenue growth and market positioning by locating, developing, defining, negotiating, and closing new business relationships.
The successful candidate will be a highly motivated self-starter, ready to dig in, get hands dirty and build our business development function from the ground up. This role will work closely with our management team, CEO, and company board to maintain and expand existing partnerships with NGO´s/IGO (Non-Governmental Organisation/Inter-Governmental Organisation) as well as identify and evaluate strategic business partners and out-licensing opportunities with the following stakeholders: NGO`s/IGO, pharmaceutical and life science organisations.

We are looking for an individual who has a deep understanding of how to identify opportunities within mentioned stakeholders, including but not limited to: identifying potential partnership targets, selling technology solutions, understanding how Ziccum’s capabilities can be used to develop a successful partnership to support our strategic objectives, and engaging with potential partners and commercial team members to execute and implement partnerships.
The ideal candidate has experience developing strategic partnerships with NGO´s/IGO´s, pharmaceutical and life science organizations, experience with customers in an externally facing role, and an understanding of global life science.

The team currently consist of 8 people with different specialties and competencies, as well as several high professional international consultants connected to the company. The position is located in Lund and will report to the CEO.

Contact information
For inquires and more information about the position, please contact Jarl Molin, senior recruitment consultants at PeakSearch. Mail: jarl.molin@peaksearch.se phone: +46 70 560 20 56
Apply for the position at PeakSearch homepage http://www.peaksearch.se or send your CV directly to Jarl, see above.